
Cutting-edge research into developing personalised mRNA vaccines for cancer patients will be accelerated following the UK’s successful Covid-jab rollout.
BioNTech, the German firm that co-produced a Covid vaccine with Pfizer, will partner with the government to deliver 10,000 personalised therapies to patients in the UK by 2030.